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ORIGINAL ARTICLE

MALE HYPOGONADISM AT A TERTIARY CARE HOSPITAL IN
KARACHI, PAKISTAN
Nanik Ram, Ali Asghar, Fauzan Hashmi, Najmul Islam
Section of Endocrinology, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan

Background: Male hypogonadism is defined as ‘inadequate gonadal function, manifested by
deficiency in gametogenesis and/or secretion of gonadal hormones’. Signs and symptoms of
hypogonadism depend primarily on the age of onset. It can be classified according to the site
primarily involved: the gonads, the hypothalamus, or the pituitary gland. The objective this study
was to determine the presentation and aetiology of male hypogonadism seen in a tertiary care
hospital. Methods: This cross-sectional study was conducted at Endocrine Clinics, Aga Khan
University Hospital Karachi. Data of male patients with hypogonadism who attended clinics
during January 2009 to August 2011 were reviewed. All male patients with clinical and
biochemical evidence of hypogonadism were included in the study. Patients with Diabetes
Mellitus, Metabolic Syndrome, Andropause, AIDS, Chronic Renal Failure, and Cirrhosis were
excluded. Mean±SD were computed for quantitative variables. Frequency and percentages were
computed for qualitative variables. Aetiology of male hypogonadism was categorised as primary
and secondary hypogonadism. Results: A total of 85 patients with male hypogonadism attended
the endocrine clinic. Mean age of patients was 25±10 years. Clinical presentations were small
genitalia (65%), absent secondary sexual characteristics (53%), not attained puberty (47%),
infertility (53%), erectile dysfunction (41%) and loss of libido (29%). Seventy-three (86%)
patients had hypogonadotrophic hypogonadism (secondary hypogonadism) and 12 (14%) patients
had hypergonadotrophic hypogonadism (primary hypogonadism). Among the patients with
hypogonadotrophic hypogonadism 38 had idiopathic hypogonadotrophic hypogonadsim, 7 had
pituitary adenoma, 6 had empty sella syndrome, 3 had Kallman’s syndrome, and 1 patient had
haemosiderosis due to thalassaemia major; 18 patients did not undergo brain imaging.
Conclusion: Small genitalia, absent secondary sexual characteristics and infertility were the main
presenting features of hypogonad men. Majority of patients had hypogonadotrophic
hypogonadsim.
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INTRODUCTION
Male hypogonadism is defined as ‘inadequate gonadal
function, manifested by deficiency in gametogenesis
and/or secretion of gonadal hormones’.1 It can be
classified according to the site primarily involved in the
hypothalamus-pituitary-gonadal axis. If the serum
testosterone level is low and FSH and LH levels are
elevated, the defect lies in the testis and
hypergonadotropic hypogonadism is present. In these
cases karyo type should be performed to rule out a
chromosomal abnormality, such as Klinefelter’s
syndrome (47, XXY; 46, XX; or 45, X/46, XY) which
may occur in 10–15% of such patients. If testosterone is
low and gonadotropins levels are low or normal, the
patient has hypogonadotropic hypogonadism due to
hypothalamic or pituitary disease.2
A detailed history, physical examination and
hormonal evaluation are required to diagnose male
hypogonadism. In certain cases, further tests are needed
to define the aetiology and the extent of Hypothalamic
Pituitary Gland axis dysfunction. These include pituitary
imaging studies, genetic studies, bone densitometry,
testicular ultrasonography, testicular biopsy, hormonal

dynamic testing and semen fluid analysis in those
patients desiring fertility.
Symptoms and signs of hypogonadism depend
primarily on the age of onset. Before puberty patient
may present with small testis, small phallus, scant pubic
and axillary hairs, disproportionately long arms and legs
and gynaecomastia. After puberty, signs and symptoms
may include decrease in muscle mass, loss of libido,
impotence,
oligospermia
or
azoospermia,
hypercholesterolemia and increase in visceral fat mass.
Hypogonadism is often unrecognised before puberty
unless it is associated with growth retardation or other
anatomic or endocrine abnormalities. In most cases the
first sign is delayed puberty, defined as ‘absence of
secondary sexual characteristics at an age more than
2SD above the population mean for the onset of
puberty’.2–6
Currently there are no studies from Pakistan on
male hypogonadism. In the West most common cause
of male hypogonadism is primary hypogonadism, i.e.,
Klinefelter’s syndrome with the prevalence of 1:500, but
we are seeing more cases of secondary hypogonadism
(pituitary and hypothalamic) mostly idiopathic
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hypogonadotrophic hypogonadism (IHH) in our
practices which is unusual compared to West.
The objective of this study was to determine
the aetiology and presentation of male hypogonadism at
a tertiary care hospital.

MATERIAL AND METHODS
This cross-sectional study was done at Endocrine
Clinics of Aga Khan University Hospital Karachi. Data
of male patients with hypogonadism who attended
clinics during January 2009 to August 2011 were
reviewed. Study was approved by Ethical Review
Committee of the Hospital.
All male patients with clinical and biochemical
(serum AM testosterone level <200 ηg/dl) evidence of
hypogonadism were included in the study. Patients with
diabetes mellitus, metabolic syndrome, andropause,
Acquired Immunodeficiency Syndrome (AIDS),
chronic renal failure, and cirrhosis were excluded.
Mean±SD were computed for quantitative
variables like age etc. Frequency and percentages were
computed for qualitative variables. Aetiology of male
hypogonadism was categorised as primary and
secondary hypogonadism.

RESULTS
A total 85 patients with male hypogonadism attended
the endocrine clinic. Mean age of patients was 25±10
years. Clinical presentations were small genitalia
(65%), absent secondary sexual characteristics (53%),
not attained puberty (47%), infertility (53%), erectile
dysfunction (41%) and loss of libido (29%). There was
no history of substance/alcohol abuse among all
patients. Among primary hypogonad patients, 3 had
history of mumps. Among secondary hypogonad
patients, 3 had anosmia/hyposmia (Table-1).
Table-1: Clinical presentation of male
hypogonadism in 85 patients
Symptoms, Sign & History
Small Genitalia
Absent Secondary Sexual Characteristics
Infertility
Not Attained Puberty
Erectile dysfunction
Loss of libido
Family History
History of Mumps
Gynaecomastia
Undescended Testis
Anosmia/Hyposmia

Frequency %
55
65
45
53
45
53
40
47
35
41
25
29
6
7
3
3.5
17
20
14
16.5
3
3.5

Seventy-three
(86%)
patients
had
hypogonadotrophic
hypogonadism
(secondary
hypogonadism) and 12 (14%) patients had
hypergonadotrophic
hypogonadism
(primary
hypogonadism).
Among
the
patients
with
hypogonadotrophic hypogonadism 38 (52%) had
idiopathic hypogonadotrophic hypogonadsim (IHH), 7
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(9.6%) had pituitary adenoma, 6 (8.2%) had empty sella
syndrome, 3 (4.1%) had Kallman’s syndrome based on
presence of anosmia/hyposmia with normal MRI brain
and one patient had hemosiderosis due to thalassaemia
major, while 18 (24.65) patients did not undergo brain
imaging (Table-2). Mean testosterone level in patients
with IHH was 27.5±40 ηg/dL (Table-3)
Table-2: Aetiology of male hypogonadism (n=85)
Aetiology
n (%)
Hypogonadotrophic hypogonadism (Secondary
73 (86)
hypogonadism)*
Idiopathic hypogonadotrophic hypogonadism (IHH) 38 (52)
7 (9.6)
Pituitary adenoma
6 (8.2)
Empty sella syndrome
3 (4.1)
Kallman’s syndrome
1 (1.3)
Haemosiderosis (Thalassaemia Major)
Hypergonadotrophic hypogonadism (Primary
12 (14)
hypogonadism)
*18 (24.65%) patients did not undergo MRI/Brain scan

Table-3: Clinical and laboratory parameters in 38
men with idiopathic hypogonadotrophic
hypogonadism
Parameters
Age (years)
Serum testosterone (ηg/dL)
Follicle stimulating hormone (IU/L)
Luteinizing hormone (IU/L)

Mean±SD
25±8.5
27.5±40
2.9±4.5
1.9±2.1

DISCUSSION
In normal male, puberty is characterised by increased
size
of
testis,
increased
penile
length,
spermatogenesis and appearance of secondary sexual
characteristics under the influence of testosterone.
We found small genitalia, absent secondary sexual
characteristics and infertility the major presenting
features which indicate pubertal deficiency of
testosterone. Patients with total testosterone level less
than 300 ηg/dL usually have signs and symptoms of
classic hypogonadism.1 In our study hypogonadotrophic hypogonadism was present in 86% of
patients and majority among them had IHH defined
as pubertal delay at 18 years of age or older, low
testosterone level with low/normal FSH and LH
levels and no pituitary or hypothalamic lesion. IHH is
a disorder caused by genetic defect in biosynthesis
and secretion of GnRH by hypothalamus or its action
on pituitary. It is five times more prevalent in men.7
Two thirds of patients with isolated GnRH deficiency
have anosmia/hyposmia (called Kallman syndrome)
and one third have normal sense of smell.8 Most
cases of Kallman syndrome are sporadic,9 but
familial occurrences is also observed. In our study,
among hypogonadotrophic hypogonadism patients 3
had Kallman syndrome. Specific genetic mutations,
i.e., DAX-1, KAL-1, FGFR1, GPR54, Prop-1, and
Hesx1, have been identified causing hypogonadotrophic hypogonadism.
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Our results concur with the study done by
Citron et al, who found primary hypogonadism in 51
patients, 164 patients had secondary hypogonadism
among 238 patients with erectile dysfunction.10 In
secondary hypogonadism group pituitary imaging was
normal in 137 (83.5%) patients, empty sella and
pituitary adenoma was found in 11 (6.7%) and 14
(8.5%) patients respectively.10
Secondary hypogonadism was not frequent in
some case series of patients evaluated for erectile
dysfunction,
unless
associated
with
hyperprolactinemia.11,12 Slag et al found 9% prevalence
of secondary hypogonadism in 188 patients with
impotency.13 In a study by Rhoden et al on pituitary
imaging in male hypogonadism, MRI pituitary was
normal in 74.5% of patients, partial empty sella in
17.6% and pituitary microadenomas were found in 7.8%
of patients, and like our study, 89% of patients younger
than 40 years had normal MRI.14
Klinefelter’s syndrome is the most common
cause of primary hypogonadism. The fundamental
chromosomal abnormality in Klinefelter’s syndrome is
the presence of one or more extra X chromosomes. The
principal karyotype in 90% of men with Klinefelter’s
syndrome is 47, XXY. In adults, the most prominent
clinical feature is very small testes size, <4 mL (<2.5
cm) in length on clinical examination.15,16 In our study
14% of patients had hypergonadotrophic hypogonadism
(primary hypogonadism); among them 3 had history of
mumps. Chromosomal analysis was not done in these
patients of Klinefelter’s syndrome. Opioids and alcohol
also cause male hypogonadism, in our study there was
no history of substance abuse.
The limitations of this study include
retrospective study, limited number of patients, and no
control group. Certain number of patients with
hypogonadotrophic hypogonadism did not undergo
brain imaging due to cost issue and were not followed
up, so aetiology in these patients remained unknown.
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